Lilly Obesity Pill Shows No Added Heart Risk in Trial

Eli Lilly & Co. said its new weight-loss pill Foundayo was at least as good as an older insulin at warding off heart attacks, strokes or other major cardiovascular events in a study, a finding that comes after US regulators asked for more safety data.

The late-stage trial compared Foundayo to Lilly’s insulin, following patients over the course of about two years. Its main objective was to assess the new pill’s ability to prevent cardiovascular emergencies in people who were at increased risk and had both diabetes and obesity.